EURL PHARMACIE CHRISTOPHE POUZARGUE : revenue, balance sheet and financial ratios

EURL PHARMACIE CHRISTOPHE POUZARGUE is a French company founded 19 years ago, specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé. Based in PUY-L'EVEQUE (46700), this company of category PME shows in 2021 a revenue of 391 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-02

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - EURL PHARMACIE CHRISTOPHE POUZARGUE (SIREN 491931317)
Indicator 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016
Revenue N/C N/C N/C N/C 390 976 € 2 266 211 € 2 058 582 € 2 087 201 € 2 012 657 € 1 988 967 €
Net income 140 901 € 62 547 € 62 526 € 170 676 € 74 470 € 131 744 € 122 948 € 134 273 € 104 151 € 118 679 €
EBITDA N/C N/C N/C N/C 75 019 € 217 671 € 208 454 € 231 951 € 163 662 € 223 893 €
Net margin N/C N/C N/C N/C 19.0% 5.8% 6.0% 6.4% 5.2% 6.0%

Revenue and income statement

In 2025, EURL PHARMACIE CHRISTOPHE POUZARGUE generates positive net income of 141 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2016-2025: 119 k€ -> 141 k€.

Net income (2025) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

140 901 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 55%. Debt remains under control: the company retains capacity to raise new debt if needed. Financial autonomy (= Equity / Total assets x 100) reaches 56%. This high autonomy means the company finances most of its assets through equity, a sign of strength.

Debt ratio (2025) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

54.608%

Financial autonomy (2025) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

56.138%

Asset age ratio (2025) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

1.2%

Solvency indicators evolution
EURL PHARMACIE CHRISTOPHE POUZARGUE

Sector positioning

Debt ratio
54.61 2025
2023
2024
2025
Q1: 13.7
Med: 49.79
Q3: 129.09
Average

In 2025, the debt ratio of EURL PHARMACIE CHRISTOPHE... (54.61) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.

Financial autonomy
56.14% 2025
2023
2024
2025
Q1: 33.42%
Med: 53.72%
Q3: 72.08%
Good

In 2025, the financial autonomy of EURL PHARMACIE CHRISTOPHE... (56.1%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 87.21. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquidity ratio (2025) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

87.214

Liquidity indicators evolution
EURL PHARMACIE CHRISTOPHE POUZARGUE

Sector positioning

Liquidity ratio
87.21 2025
2023
2024
2025
Q1: 131.03
Med: 182.25
Q3: 258.64
Watch

In 2025, the liquidity ratio of EURL PHARMACIE CHRISTOPHE... (87.21) ranks in the bottom 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio below 1 may signal potential cash flow tensions.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.

Operating WCR (2025) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

0 €

Customer credit (2025) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

0 j

Supplier credit (2025) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

0 j

Inventory turnover (2025) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

0 j

WCR and payment terms evolution
EURL PHARMACIE CHRISTOPHE POUZARGUE

Positioning of EURL PHARMACIE CHRISTOPHE POUZARGUE in its sector

Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé

Valuation estimate

Based on 277 transactions of similar company sales in 2025, the value of EURL PHARMACIE CHRISTOPHE POUZARGUE is estimated at 2 238 229 € (range 1 518 872€ - 3 512 089€). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.

Estimated enterprise value 2025
277 transactions
1518k€ 2238k€ 3512k€
2 238 229 € Range: 1 518 872€ - 3 512 089€
NAF 5 année 2025

Valuation method used

Net Income Multiple
140 901 € × 15.9x = 2 238 229 €
Range: 1 518 873€ - 3 512 090€

Only this financial indicator is available for this company.

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 277 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)

Compare EURL PHARMACIE CHRISTOPHE POUZARGUE with other companies in the same sector:

Voir toutes les statistiques du secteur Commerce de détail de produits pharmaceutiques en magasin spécialisé

Frequently asked questions about EURL PHARMACIE CHRISTOPHE POUZARGUE

What is the revenue of EURL PHARMACIE CHRISTOPHE POUZARGUE ?

The revenue of EURL PHARMACIE CHRISTOPHE POUZARGUE in 2021 is 391 k€.

Is EURL PHARMACIE CHRISTOPHE POUZARGUE profitable?

Yes, EURL PHARMACIE CHRISTOPHE POUZARGUE generated a net profit of 141 k€ in 2025.

Where is the headquarters of EURL PHARMACIE CHRISTOPHE POUZARGUE ?

The headquarters of EURL PHARMACIE CHRISTOPHE POUZARGUE is located in PUY-L'EVEQUE (46700), in the department Lot.

Where to find the tax return of EURL PHARMACIE CHRISTOPHE POUZARGUE ?

The tax return of EURL PHARMACIE CHRISTOPHE POUZARGUE is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does EURL PHARMACIE CHRISTOPHE POUZARGUE operate?

EURL PHARMACIE CHRISTOPHE POUZARGUE operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.